. 2014 Feb;21(1):35–42. doi: 10.3747/co.21.1855

TABLE IV.

Common hematologic adverse events associated with bendamustine monotherapy in first-line chronic lymphocytic leukemia (cll) and rituximab-refractory indolent B-cell non-Hodgkin lymphoma (inhl)^a

Event	Occurrence (%) during therapy for
	inhl		cll

	All grades	Grade 3 or 4^b	All grades	Grade 3 or 4^b
Neutropenia	45	42	27	23
Thrombocytopenia	37	10	23	12
Anemia	36	16	19	2

Adapted from Lundbeck Canada¹.

Criteria: neutropenia, less than 1.0×10⁹/L; thrombocytopenia, less than 50×10⁹/L; anemia, hemoglobin less than 80 g/L²¹.